Coronavirus vaccine

US11596686B2 · kind B2 · utility

Assignee

• CureVac SE · DE

Inventors

• Susanne RAUCH · Tübingen, DE
• Hans Wolfgang GROßE · Tübingen, DE
• Benjamin PETSCH · Tübingen, DE

Key dates

• Filing date: Aug 9, 2022
• Grant date: Mar 7, 2023
• Expiry date: Aug 9, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/20034
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.